Voyager Therapeutics reports Q4 net income $56.4M, pro-forma cash $431M, pipeline milestones

Voyager Therapeutics, Inc.

2023-FY EPS reported $2.97 revenue$250,008,000

Q4 collaboration revenue $90.1M (vs -$1.6M YoY), net income $56.4M (vs loss $23.6M).
FY 2023 collaboration revenue $250.0M (vs $40.9M), net income $132.3M (vs loss $46.4M).
Pro-forma cash $431M after Novartis $100M and Jan 2024 $100M public offering; runway into 2027.
Selected development candidates: SOD1 ALS gene therapy (IND mid-2025) and Friedreich's ataxia (triggered $5M milestone, clinic 2025).
Novartis collaboration: $80M upfront + $20M equity, up to $1.2B milestones; VY-TAU01 IND expected H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Voyager Therapeutics, Inc. reported Q4 2023 results: revenue $90.1 million, net income $56.4 million.

Period: Q4 2023
Revenue: $90.1 million
Net income: $56.4 million
Result: reported results

Exact text from the filing

Voyager had collaboration revenue of $90.1 million for the fourth quarter of 2023

View on SEC.gov

1048 earnings releases filed in the last 30 days. Browse all earnings releases →

Voyager Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-001987

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.